Lymphir

Citiusā€™ IL-2 Therapy Fails to Win FDA Approval for Lymphoma

FDA rejects Citius’ resurrected IL-2 lymphoma treatment

SG Tylor

Source – Citius PharmaceuticalsĀ  The FDA has declined Citius Pharmaceuticals’ request to market Lymphir, an updated version of a lymphoma ...